Clinical Trial Search

Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants

Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137

Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients

Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation

Primary: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period — 3; 37 Participants — p=<0.0001

Primary: Occurrence of Symptomatic Venous Thromboembolic Events — 19; 5 participants

Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…

Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05

Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001

Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants

Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants

Primary: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event — 67; 71 Participants — p=0.0056

Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants

Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…

Primary: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital — 11966; 1979 Participants

Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…

Primary: Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population — 2.71…

Primary: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism — 13; 17; 50; 8 participants — p=0.0001

Primary: Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 53; 75; 60 Participants — p=0.5648

Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…

Primary: Subjects With Major Adverse Events — 24; 964 Participants

Primary: Comparison of Thrombin Induced Platelet-fibrin Clot Strength (TIP-FCS) Between Patients With and Without Device Related Thrombosis (DRT) Assessed at 1-year of Watchman…

Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants

Primary: Hypercoagulability — 16; 18 participants

Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 61; 69 Participants — p=< 0.0001

Primary: Cardiovascular Event - Myocardial Infarction, Stroke, Death — 17; 6 Participants — p=0.007

Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity

Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56

Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants

Primary: Incidence of Subjects With Venous Thromboembolism Events — 2.4; 6.9 percentage of subjects with vte events — p=<0.001